A Phase 1 interventional study of Simvastatin (10mg, 20mg, 40mg) and Rosuvastatin (5mg, 20mg, 40mg) in Diabete Mellitus and Lipid Profile, sponsored by Shaheed Benazir Bhutto University Sheringal Dir Upper. Not yet recruiting at 2 sites in Pakistan. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by Shaheed Benazir Bhutto University Sheringal Dir Upper · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing simvastatin in Diabetes Mellitus — 2 open to participants now, 2 under way, none of them phase 3. Simvastatin · Diabetes Mellitus.
Among the 11 studies testing simvastatin in Diabetes Mellitus, this one is the 5th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is the only one in phase 1, and was the 11th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →2 of the 11 studies testing simvastatin in Diabetes Mellitus are open now, in 2 countries. Recruiting first, the newest first:
The University of Hong Kong · Sites in Hong Kong
Ages 50–74 · Women only
By country, each count listing its studies:
Simvastatin: first FDA approval 1991 (ZOCOR), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 3 · Phase 4 5
First in 1991; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 95 across the 10 interventional studies. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 11 have an industry lead sponsor. The 10 most frequent:
Shaheed Benazir Bhutto University Sheringal Dir Upper is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Shaheed Benazir Bhutto University Sheringal Dir Upper has 1 study filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
1 of the studies testing simvastatin in Diabetes Mellitus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07378293Shaheed Benazir Bhutto University Sheringal Dir UpperEffects of Selected Statins on Blood Glucose Levels in Healthy Volunteers | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing simvastatin in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Phase I randomized clinical trial aims to investigate the short-term effects of three commonly prescribed statins (atorvastatin, rosuvastatin, and simvastatin) at different dose levels on blood glucose homeostasis in healthy volunteers. The study will assess changes in fasting blood glucose, insulin, and C-peptide levels following two days of statin administration under controlled conditions. The research seeks to provide comparative data on the potential diabetogenic effects of these medications.
This study addresses emerging evidence suggesting statin therapy may modestly increase diabetes risk in a dose-dependent manner. The trial will enroll healthy volunteers who will be randomized to receive one of three statins at low, moderate, or high doses for two days. Blood glucose will be measured using standardized glucometers, while insulin and C-peptide levels will be determined using ELISA assays. The study aims to clarify whether different statins have varying effects on glucose metabolism during short-term exposure and to establish dose-response relationships.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The assigned participants will be given Rosuvastatin 5mg, 20mg, 40mg OD for two days
Drug: Rosuvastatin (5mg, 20mg, 40mg)
The assigned participants will be given Atorvastatin 10mg,20mg, 40mg OD for two days
Drug: Atorvastatin (10mg, 20mg, 40mg)
The assigned participants will be given Simvastatin 10mg, 20mg, 40mg OD for two days
Drug: Simvastatin (10mg, 20mg, 40mg)
The Simvastatin (10mg, 20mg, 40mg) group participants will be given the drug orally OD for two days
Also known as: Simvastatin
The Rosuvastatin (5mg, 20mg, 40mg) group participants will be given the drug orally OD for two days
Also known as: Rosuvastatin
The Atorvastatin (10mg, 20mg, 40mg) group participants will be given the drug orally OD for two days
Also known as: Atorvastatin
Blood Glucose Measurements
Blood glucose of the subjects will be determined by glucometer in mg/dl
Time frame: before dosing and 2 days after dosing
Insulin Levels Determination
Blood insulin levels of each participants will be checked by using human insulin ELISA kit 96 wells on respective peak plasma concentration of respective statin
Time frame: Before dosing and two days after dosing
C- Peptide determination
Blood samples approx. 4 mL will be taken from the participants to check C- Peptide levels by using human peptide C ELISA kit on respective peak plasma concentration of respective statin
Time frame: Before dosing and after two days of Dosing
Plan to share: Yes — The study results will be shared in Journals without the participant identifiers.
Supporting information: Clinical study report
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Dec 2026, 9 months later.
Of 76 non-industry phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 55. This study's planned 9 months is below that.
Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Simvastatin · Rosuvastatin · Atorvastatin
Shaheed Benazir Bhutto University Sheringal Dir Upper